News & Events
Insight Genetics and National Cancer Institute Collaborate to Develop New Technologies for Clinical Trials
NCI—through the CADP—will support Insight Genetics by providing services of two CLIA-certified labs that will further validate the assay, access to clinical samples, subject matter expertise, and statistical consultation. This collaboration is the continuation of a successful relationship between NCI and Insight Genetics. In the last three years the molecular diagnostics company has been awarded four contracts from NCI for the development of companion diagnostics.
For anyone wondering about a key pharmaceutical change, consider these words from JonEric Pettersson, manager of commercial development at Insight Genetics (Nashville, Tenn.): “Less than 1% of current drugs have a companion diagnostic, and 60% of the drugs in clinical trials have a companion diagnostic in mind.” He adds, “Companion diagnostics are an important component in moving the ball forward in personalized medicine.” Making those moves depends on biomarkers.
Through federal grants and collaborations, local companies are making strides in growing Nashville's life sciences industry, which has played second fiddle to the hospital industry in growing the city’s reputation as a health care capital.
Nashville Medical News profiles the progress of Insight Genetics following recent announcements pertaining to the continued globalization of its products. In addition to continuing its work with QIAGEN to expand access to reliable and efficient tests to identify cancer-causing mutations of anaplastic lymphoma kinase (ALK) in lung cancer, the Insight Genetics team is currently developing a test to expose a biomarker for triple negative breast cancer.